# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Leerink Partners analyst Mike Kratky upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Market Perform to Outperform and raise...
Stifel analyst Mathew Blackman maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Buy and raises the price target from $37 ...
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target fro...
Wall Street is set to break a two-day losing streak on Tuesday, as major indices trended positively during midday trading in Ne...
U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday.
Stifel analyst Mathew Blackman upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and raises the price target from...
Stifel analyst Mathew Blackman upgrades Tandem Diabetes Care (NASDAQ:TNDM) from Hold to Buy and announces $37 price target.